Vascular endothelial growth factor-A mRNA gene expression in clinical phases of multiple sclerosis

Rasol, Hoiyda A. Abdel; Helmy, Hanan; El-Mously, Sherine; Aziz, Margeret A.; bahaie, Hossam El

doi:10.1177/0004563215584957

Cited by 6 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have identified VEGF as a potent modulator of nociceptive signalling. Importantly, other disorders with chronic neuropathic pain, such as multiple sclerosis, have also been linked to disturbances in the VEGF signalling system (Rasol et al 2016). Furthermore, VEGF-A 165 b administration has been shown to reduce nociceptive measures suggesting that there could be a commonality of vascular disruption (that can be rescued by VEGF-A 165 b) in the development of neuropathic pain across disorders (Hulse et al 2014).…”

Section: Journal Clubmentioning

confidence: 99%

VEGF‐A₁₆₅b to the rescue: vascular integrity and pain sensitization

Jere

Cassidy

2018

The Journal of Physiology

View full text Add to dashboard Cite

Section: Journal Clubmentioning

confidence: 99%

VEGF‐A₁₆₅b to the rescue: vascular integrity and pain sensitization

Jere

Cassidy

2018

The Journal of Physiology

View full text Add to dashboard Cite

The evaluation of VEGF and HIF‐1α gene polymorphisms and multiple sclerosis susceptibility

Saravani

Rokni

Mehrbani

et al. 2019

The Journal of Gene Medicine

View full text Add to dashboard Cite

BackgroundMultiple sclerosis (MS) is an autoimmune disease that leads to myelin sheath destruction. Hypoxia‐inducible factor 1 (HIF‐1) has several roles in cells, such as inducing inflammation and angiogenesis. Recently, several lines of evidence have indicated the role of the hypoxia response and the HIF‐1 signaling pathway in an autoimmune disease such as MS. The present study aimed to evaluate the effects of HIF‐1α gene polymorphisms and vascular endothelial growth factor (VEGF) (as a major target gene of HIF‐1α) gene polymorphism on MS susceptibility.MethodsIn total, 150 MS patients and 150 healthy age‐ and gender‐matched people as a control group participated in the present study. The polymerase chain reaction‐restriction fragment length polymorphism method was used for genotyping.ResultsThe results obtained showed that the CC genotype of the VEGF rs699947 polymorphism was significantly higher in the case group than in the control group (p = 0.004). Also, we showed a significant relationship between the VEGF rs699947 polymorphism and MS in a dominant inheritance model (p = 0.005). Regarding the VEGF rs699947 polymorphism allelic distribution, the C allele frequency was significantly higher in the control group than in the case group (71.3% versus 61%, respectively, p = 0.009) and decreased the MS susceptibility by 1.6‐fold (odds ratio = 1.6, 95% confidence interval = 1.2–2.2). There was no significant difference between the two groups with respect to HIF‐1α rs11549465 genotypic distribution. The HIF‐1α C111A polymorphism was non‐polymorphic in our study population, except in the case group where nine subjects carried the CA genotype.ConclusionsWe show a significant association between VEGF rs60047 polymorphism and MS susceptibility. However, our results do not show a significant association between MS and HIF‐1α polymorphisms.

show abstract

Genetic and Molecular Biology of Multiple Sclerosis Among Iranian Patients: An Overview

Moghbeli

2019

Cell Mol Neurobiol

View full text Add to dashboard Cite

Vascular endothelial growth factor-A mRNA gene expression in clinical phases of multiple sclerosis

Abstract: A lower vascular endothelial growth factor A mRNA gene expression level was independently associated with a higher risk of multiple sclerosis.

Cited by 6 publications

References 31 publications

VEGF‐A₁₆₅b to the rescue: vascular integrity and pain sensitization

VEGF‐A₁₆₅b to the rescue: vascular integrity and pain sensitization

The evaluation of VEGF and HIF‐1α gene polymorphisms and multiple sclerosis susceptibility

Genetic and Molecular Biology of Multiple Sclerosis Among Iranian Patients: An Overview

Contact Info

Product

Resources

About

Vascular endothelial growth factor-A mRNA gene expression in clinical phases of multiple sclerosis

Abstract: A lower vascular endothelial growth factor A mRNA gene expression level was independently associated with a higher risk of multiple sclerosis.

Cited by 6 publications

References 31 publications

VEGF‐A165b to the rescue: vascular integrity and pain sensitization

VEGF‐A165b to the rescue: vascular integrity and pain sensitization

The evaluation of VEGF and HIF‐1α gene polymorphisms and multiple sclerosis susceptibility

Genetic and Molecular Biology of Multiple Sclerosis Among Iranian Patients: An Overview

Contact Info

Product

Resources

About

VEGF‐A₁₆₅b to the rescue: vascular integrity and pain sensitization

VEGF‐A₁₆₅b to the rescue: vascular integrity and pain sensitization